Summit Corporation PLC
Records under this name other than patents Summit Corporation PLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Summit Corporation PLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,975,416 | Antibacterial Compounds Formerly held In force · High confidence | In force | High confidence | |
| US 9,314,456 | Antibacterial compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,842,784 | Treatment of energy utilization disease Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,308 | Compounds for the Treatment of Clostridium Difficile-Associated Disease Formerly held In force · High confidence | In force | High confidence | |
| US 8,481,583 | Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea Formerly held Lapsed on the fee record Ended Jul 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 9, 2025 | From the USPTO record |
| US 9,278,091 | Compounds for the treatment of Clostridium difficile associated disease Formerly held Lapsed on the fee record Ended Mar 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2024 | From the USPTO record |
| US 8,518,980 | Treatment of Duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Aug 27, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2021 | From the USPTO record |
| US 8,501,713 | Drug combinations for the treatment of duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Aug 6, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2021 | From the USPTO record |
| US 9,492,433 | Pharmaceutical composition for the treatment of Duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Nov 15, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2020 | From the USPTO record |
| US 8,138,351 | Treatment of duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Mar 20, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 20, 2020 | From the USPTO record |